Treatment En 2011 Final
-
Upload
zenagit123456 -
Category
Documents
-
view
217 -
download
0
Transcript of Treatment En 2011 Final
-
8/3/2019 Treatment En 2011 Final
1/83
Part 2: Recommendations for
Hypertension Treatment
2011 Canadian Hypertension
Education ProgramRecommendations
-
8/3/2019 Treatment En 2011 Final
2/83
The full slide set of the2011 CHEP Recommendations
are available at
www.hypertension.ca
-
8/3/2019 Treatment En 2011 Final
3/83
2011 Canadian Hypertension EducationProgram (CHEP)
A red flag has been posted whererecommendations were updated for 2011.
Slide kits for health care professional and publiceducation can be downloaded (English and Frenchversions) from www.hypertension.ca
-
8/3/2019 Treatment En 2011 Final
4/83
2011 Canadian Hypertension EducationProgram (CHEP)
Treatment Approaches:
Lifestyle
Pharmacological
-
8/3/2019 Treatment En 2011 Final
5/83
Key CHEP Messages for theManagement of Hypertension
1. Assess blood pressure at all appropriate visits.
2. Promote a healthy lifestyle to lower blood pressure and reducethe risk of cardiovascular disease at each visit with interventionsto reduce high dietary sodium, for smoking cessation, to reduceabdominal obesity, to promote a healthy weight, to increase
physical activity and to manage dyslipidemia and dysglycemia.3. Treat blood pressure to less than 140/90 mmHg in most people
and to less than 130/80 mmHg in people with diabetes orchronic kidney disease using a combination of drugs andlifestyle modifications.
4. Advocate for healthy public policies to prevent hypertension and
advance the health of patients and populations.5. Keep up to date with resources for the prevention and control of
hypertension by registering at www.htnupdate.ca anddownloading and ordering tools at www.hypertension.ca/tools.
-
8/3/2019 Treatment En 2011 Final
6/83
The Canadian Hypertension EducationProgram: 2011 Recommendations
Whats new?
Increased emphasis on the use of single pillcombinations (and more guidance on whichcombinations to use).
In stroke patients avoid excessive blood pressurereductions, except in the setting of the most severeelevations
The most important step in prescription of
antihypertensive therapy is achieving patient buy-in:new tips for improving adherence
-
8/3/2019 Treatment En 2011 Final
7/83
For your patients ask themto sign up atwww.myBPsite.ca for freeaccess to the latest
information & resources onhigh blood pressure
For health care professionals sign up atwww.htnupdate.ca forautomatic updates and on
current hypertensioneducational resources
-
8/3/2019 Treatment En 2011 Final
8/83
The Canadian Hypertension EducationProgram: 2011 Recommendations
Whats old but still important?
Out-of-office blood pressure measurements areimportant in both the diagnosis and management of
hypertension Lifestyle changes are still a critical component of
hypertension management (and prevention!)
The management of hypertension is all about global
risk management and vascular protection
-
8/3/2019 Treatment En 2011 Final
9/83
Recommendations 2011Table of contents
I. Indications for drug therapyII. Goals of therapyIII. AdherenceIV. LifestyleV. Uncomplicated
VI. CV IHDVII. CHFVIII. Cerebrovascular / StrokeIX. LVHX. Chronic kidney diseaseXI. RenovascularXII. DiabetesXIII. SmokingXIV.Overall risk reduction
-
8/3/2019 Treatment En 2011 Final
10/83
I. Indications for
Pharmacotherapy
2011 Canadian Hypertension
Education ProgramRecommendations
-
8/3/2019 Treatment En 2011 Final
11/83
I. Indications for Pharmacotherapy
Usual blood pressure threshold values for initiation
of pharmacological treatment of hypertension
Condition Initiation
SBP or DBP mmHg
Systolic or Diastolic hypertension u140/90
Diabetes
Chronic Kidney Disease
u130/80
-
8/3/2019 Treatment En 2011 Final
12/83
I. Indications for Pharmacotherapyafter diagnosis of hypertension (1)
Patients at low risk with stage 1 hypertension(140-159/90-99 mmHg) lifestyle modification can be the sole therapy.
Patients with target organ damage (e.g. left
ventricular hypertrophy) (140-159/90-99 mmHg)
Treat with pharmacotherapy
Patients with diabetes or chronic kidney diseaseshould be considered for pharmacotherapy if the
blood pressure is equal or over 130/80 mmHg
-
8/3/2019 Treatment En 2011 Final
13/83
I. Indications for Pharmacotherapyafter diagnosis of hypertension (2)
Patients with other risk factors (over 90% ofCanadians with hypertension have other risk factors)(140-159/90-99 mmHg despite lifestyle modification)
Treat with pharmacotherapy
Treatment Gap Alert: Many younger hypertensiveCanadians with multiple cardiovascular risks arecurrently not treated with pharmacotherapy. Health
care professionals need to be aware of this importantcare gap and recommend pharmacotherapy.
-
8/3/2019 Treatment En 2011 Final
14/83
II. Goals of Therapy
2011 Canadian Hypertension
Education ProgramRecommendations
-
8/3/2019 Treatment En 2011 Final
15/83
II. Goals of Therapy
Blood pressure target values for treatment of
hypertension
Condition Target
SBP and DBP mmHgIsolated systolic hypertension
-
8/3/2019 Treatment En 2011 Final
16/83
II. Goals of Therapy
To optimally reduce cardiovascular risk reduce theblood pressure to specified targets.
This usually requires two or more drugs and lifestylechanges
The systolic target is more difficult to achieve howevercontrolling systolic blood pressure is as important if not moreimportant than controlling diastolic blood pressure
-
8/3/2019 Treatment En 2011 Final
17/83
Follow-up of blood pressureabove targets
Patients with blood pressure above target arerecommended to be followed at least every 2ndmonth
Follow-up visits are used to increase the intensity oflifestyle and drug therapy, monitor the response totherapy and assess adherence
-
8/3/2019 Treatment En 2011 Final
18/83
III. Adherence
2011 Canadian HypertensionEducation Program
Recommendations
-
8/3/2019 Treatment En 2011 Final
19/83
III. Adherence to anti-hypertensive managementcan be improved by a multi-pronged approach
Assess adherence to pharmacological and non-pharmacological therapy at every visit
Teach patients to take their pills on a regular scheduleassociated with a routine daily activity e.g. brushing
teeth. Simplify medication regimens using long-acting once-
daily dosing
Utilize fixed-dose combination pills
Utilize unit-of-use packaging e.g. blister packaging Replacing multiple pill antihypertensive combinations
with single pill combinations!
-
8/3/2019 Treatment En 2011 Final
20/83
III. Adherence to anti-hypertensive managementcan be improved by a multi-pronged approach
Encourage greater patient responsibility/autonomy inregular monitoring of their blood pressure
Educate patients and patients' families about their
disease/treatment regimens verbally and in writing Use an interdisciplinary care approach coordinating
with work-site health care givers and pharmacists ifavailable
-
8/3/2019 Treatment En 2011 Final
21/83
IV. Lifestyle management
2011 Canadian Hypertension
Education ProgramRecommendations
-
8/3/2019 Treatment En 2011 Final
22/83
Lifestyle Recommendations forPrevention andTreatment of Hypertension
To reduce the possibility of becoming hypertensive,
Reduce sodium intake to less than 1500 mg/day
Healthy diet: high in fresh fruits, vegetables, low fat dairy products,dietary and soluble fibre, whole grains and protein from plant sources,low in saturated fat, cholesterol and salt in accordance with Canada'sGuide to Healthy Eating.
Regular physical activity: accumulation of 30-60 minutes of moderateintensity dynamic exercise 4-7 days per week in addition to dailyactivities
Low risk alcohol consumption (2 standard drinks/day and less than14/week for men and less than 9/week for women)
Attaining and maintaining ideal body weight (BMI 18.5-24.9 kg/m2)
W
aistC
ircumference MenW
omen Europid, Sub-Saharan African, Middle Eastern
-
8/3/2019 Treatment En 2011 Final
23/83
Dietary Sodium
Less than 2300mg / day
(Most of the salt in food is hidden and comesfrom processed food)
Dietary Potassium
Daily dietary intake >80 mmol
Calcium supplementation
No conclusive studies for hypertension
Magnesium supplementation
No conclusive studies for hypertension
Lifestyle Recommendations for Hypertension:Dietary
High in: Fresh fruits Fresh vegetables
Low fat dairy products Dietary and soluble fibre Plant protein
Low in:
Saturated fat and cholesterol Sodium
www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php.
-
8/3/2019 Treatment En 2011 Final
24/83
Potential Benefits of a Wide Spread Reductionin Dietary Sodium in Canada
1 million fewer hypertensives
5 million fewer physicians visits a year for hypertension
Health care cost savings of $430 to 540 million per year relatedto fewer office visits, drugs and laboratory costs for hypertension
Improvement of the hypertension treatment and control rate
13% reduction in CVD
Total health care cost savings of over $1.3 billion/year
Penz ED, Cdn J Cardiol 2008.Joffres MR_CJC_ 23(6) 2007.
REDUCTION IN AVERAGE DIETARY SODIUM FROMABOUT 3500 MG TO 1700 MG
-
8/3/2019 Treatment En 2011 Final
25/83
Recommendations for daily salt intake
2,300 mg sodium (Na)
= 100 mmol sodium (Na)
= 5.8 g of salt (NaCl)
= 1 level teaspoon of
table salt
80% of average sodium intake is in processed foods
Only 10% is added at the table or in cooking
Age Recommended
Intake
19-50 1500
51-70 1300
71 and over 1200
Institute of Medicine, 2003
-
8/3/2019 Treatment En 2011 Final
26/83
Sodium: Meta-analyses
The Cochrane Library2006;3:1-41
Average Reduction of sodiumin mg/day
1800 mg/day
2300 mg/day
HypertensivesReduction of BP
5.1 / 2.7 mmHg
7.2/3.8 mmHg
Average Reduction of sodiumin mg/day
1700 mg/day
2300 mg/day
NormotensivesReduction of BP
2.0 / 1.0 mmHg
3.6/1.7 mmHg
-
8/3/2019 Treatment En 2011 Final
27/83
2011 Canadian Hypertension EducationProgram (CHEP)
Important messages from past recommendations
High dietary sodium is estimated to increase blood pressure inthe Canadian population to the extent that 1,000,000 Canadiansmeet the diagnostic criteria for hypertension who wouldotherwise have normal blood pressure
Most of the sodium in Canadian diets comes from processedfoods and restaurants.
Pizza, breads, soups and sauces usually have high amounts ofsodium
Patient information on how to achieve a reduced sodium diet
can be found at www.hypertension.ca Aim to reduce sodium intake to less than 1500 mg/day to
prevent and control hypertension
-
8/3/2019 Treatment En 2011 Final
28/83
Reduce Your Sodium Intake
At home
Plan meals at least a day in advance.
Make more meals from unprocessed foods.
Gradually decrease the amount of salt used in cooking and atthe table (this includes sea salt).
Use condiments sparingly.
Flavour food with lemon juice, fresh garlic, spices, herbs andflavoured vinegars.
Try low-sodium seasoning mixes.
Cook and bake with vegetable oil rather than butter ormargarine.
Use tomato paste instead of tomato sauce or soup in recipes.
-
8/3/2019 Treatment En 2011 Final
29/83
Reduce Your Sodium Intake
At the grocery store
Buy pre-prepared, convenience foods that are low in sodiumsuch as frozen vegetables, frozen shrimp, skinless & bonelesschicken breasts and pre-cut salads and fruit.
Choose unsalted snack foods such as pretzels, nuts, seeds andcrackers.
Read food labels and compare sodium content between similarfoods
Look for foods labelled salt-free, no added salt, low in sodium,or reduced in sodium.
Always check the Nutrition Facts table
-
8/3/2019 Treatment En 2011 Final
30/83
Reduce Your Sodium Intake
When eating or taking out
Choose salads and meals made with foods low in sodium
Ask for no salt or MSG to be added during cooking
Ask for sauces, spreads or dressings on the side and usesparingly
Limit fast foods and take-out meals.
-
8/3/2019 Treatment En 2011 Final
31/83
Exercise should be prescribed as an adjunctive to pharmacological therapy
Lifestyle Recommendations for Hypertension:Physical Activity
Should be prescribed to reduce blood pressure
Frequency - Four to seven days per weekF
Intensity - ModerateI
Time - 30-60 minutesT
Type Cardiorespiratory Activity- Walking, jogging
- Cycling- Non-competitive swimming
T
-
8/3/2019 Treatment En 2011 Final
32/83
Lifestyle Recommendations for Hypertension:Weight Loss
Height, weight, and waist circumference (WC) should be measured
and body mass index (BMI) calculated for all adults.
Hypertensive and all patients
BMI over 25- Encourage weight reduction- Healthy BMI: 18.5-24.9 kg/m2
Waist Circumference Men Women- Europid, Sub-Saharan African, Middle Eastern
-
8/3/2019 Treatment En 2011 Final
33/83
Courtesy J.P. Desprs 2006
Measure here
Iliac crest
Waist Circumference Measurement
-
8/3/2019 Treatment En 2011 Final
34/83
Lifestyle Recommendations for Hypertension:Alcohol
Low risk alcohol consumption
Women: maximum of 9 standard drinks/week
Men: maximum of 14 standard drinks/week
0-2 standard drinks/day
A standard drink is about 142 ml or 5 oz of wine (12% alcohol). 341 mL or
12 oz of beer (5% alcohol) 43 mL or 1.5 oz of spirits (40% alcohol).
-
8/3/2019 Treatment En 2011 Final
35/83
Lifestyle Recommendations for Hypertension:Stress Management
Hypertensive patientsin whom stress appears to be an important issue
Individualized cognitive behavioural interventions aremore likely to be effective when relaxation techniques
are employed.
Stress management
Behaviour Modification
-
8/3/2019 Treatment En 2011 Final
36/83
Impact of Lifestyle Therapies on Blood Pressurein Hypertensive Adults
Intervention Intervention SBP/DBP
Reduce sodium intake-1800 mg/day sodium
Hypertensive
-5.1 / -2.7
Weight loss per kg lost -1.1 / -0.9
Alcohol intake -3.6 drinks/day -3.9 / -2.4
Aerobic exercise 120-150 min/week -4.9 / -3.7
Dietary patternsDASH diet
Hypertensive -11.4 / -5.5
Padwal R. et al. CMAJ SEPT. 27, 2005; 173 (7) 749-751
-
8/3/2019 Treatment En 2011 Final
37/83
Lifestyle Therapies in HypertensiveAdults: Summary
Intervention Target
Reduce foods withadded sodium
< 2300 mg /day
Weight loss BMI
-
8/3/2019 Treatment En 2011 Final
38/83
Epidemiologic impact on mortality of bloodpressure reduction in the population
Reduction in SBP(mmHg)
% Reduction in Mortality
Stroke CHD Total
2 -6 -4 -3
3 -8 -5 -4
5 -14 -9 -7
Adapted from Whelton, P. K. et al. JAMA 2002;288:1882-1888
AfterIntervention
BeforeIntervention
Reduction in BPPrevalence%
-
8/3/2019 Treatment En 2011 Final
39/83
V. Pharmacotherapy
2011 Canadian HypertensionE
ducationP
rogramRecommendations
-
8/3/2019 Treatment En 2011 Final
40/83
V. Choice of Pharmacological TreatmentUncomplicated
Associated risk factors?
or
Target organ damage/complications?
or
Concomitant diseases/conditions?
IndividualizedTreatment(and compelling
indications)
YES
Treatment in theabsence of compelling
indications for specific
therapies
NO
-
8/3/2019 Treatment En 2011 Final
41/83
V. Choice of Pharmacological Treatment
1. Treatment of Systolic/Diastolic hypertensionwithout other compelling indications
2. Treatment of Isolated Systolic hypertension without
other compelling indications
-
8/3/2019 Treatment En 2011 Final
42/83
V. Treatment of Adults with Systolic/DiastolicHypertension without Other Compelling Indications
TARGET 20
mmHg systolic or >10 mmHg diastolic above target
-
8/3/2019 Treatment En 2011 Final
43/83
V. Considerations Regarding the Choice ofFirst-Line Therapy
Use caution in initiating therapy with 2 drugs in whom adverseevents are more likely (e.g. frail elderly, those with posturalhypotension or who are dehydrated).
ACE inhibitors, renin inhibitors and ARBs are contraindicated inpregnancy and caution is required in prescribing to women of childbearing potential.
Beta adrenergic blockers are not recommended for patients age 60and over without another compelling indication.
Diuretic-induced hypokalemia should be avoided through the use ofpotassium sparing agents if required.
The use of dual therapy with an ACE inhibitor and an ARB should
only be considered in selected and closely monitored people withadvanced heart failure or proteinuric nephropathy.
ACE-inhibitors are not recommended (as monotherapy)for black patients without another compelling indication.
-
8/3/2019 Treatment En 2011 Final
44/83
V. Add-on Therapy for Systolic/DiastolicHypertension without Other Compelling Indications
IF BLOOD PRESSURE IS NOT
CONTROLLED CONSIDER Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect
If blood pressure is still not controlled, or there are adverse effects,
other classes of antihypertensive drugs may be combined (such as
alpha blockers or centrally acting agents).
2. Triple or Quadruple Therapy
1. Add-on Therapy
If partial response to monotherapy
-
8/3/2019 Treatment En 2011 Final
45/83
Drug Combinations
When combining drugs, use first-line therapies.
Two drug combinations of beta blockers, ACEinhibitors and angiotensin receptor blockers have notbeen proven to have additive hypotensive effects.
Therefore these potential two drug combinationsshould not be used unless there is a compelling (nonblood pressure lowering) indication
Combinations of an ACEI with an ARB do not reducecardiovascular events more than the ACEI alone andhave more adverse effects therefore are notgenerally recommended
-
8/3/2019 Treatment En 2011 Final
46/83
Drug Combinations contd
Caution should be exercised in combining a nondihydropyridine CCB and a beta blocker to reducethe risk of bradycardia or heart block.
Monitor serum creatinine and potassium when
combining K sparing diuretics, ACE inhibitors and/orangiotensin receptor blockers.
If a diuretic is not used as first or second line therapy,triple dose therapy should include a diuretic, when
not contraindicated.
-
8/3/2019 Treatment En 2011 Final
47/83
Medication Use and BP Controlin ALLHAT
0
20
40
60
80
100
Baseline 6 mo 1 y 3 y 5 y
%
3 Drugs
2 Drugs
1 drug
% controlled-
Canadian sites
Cushman et al. J Clin Hypertens2002;4:393-404
-
8/3/2019 Treatment En 2011 Final
48/83
Ratio of Incremental SBP lowering effect atstandard dose Combine or Double?
1.04 1
1.16
0.891.01
0.19 0.23 0.2
0.37
0.22
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Thiazide -blocker ACE-I CCB All
Combine Double
Inc
remenalSBPr
ed
uctionratio
Ob
served/Expected
(additive)
Wald et al, Combination Versus Monotherapy for Blood Pressure Reduction,The American Journal of Medicine, Vol 122, No 3, March 2009
-
8/3/2019 Treatment En 2011 Final
49/83
BP lowering effects from antihypertensive drugs
Dose response curves for efficacy are relatively flat
80% of the BP lowering efficacy is achieved at half-standard dose
Combinations of standard doses have additive bloodpressure lowering effects
Law. BMJ 2003
-
8/3/2019 Treatment En 2011 Final
50/83
V. Summary: Treatment of Systolic-DiastolicHypertension without Other Compelling Indications
CONSIDER
Nonadherence Secondary HTN Interfering drugs or
lifestyle White coat effect
Dual Combination
Triple or Quadruple
Therapy
Lifestyle modification
Thiazidediuretic
ACEILong-acting
CCBBeta-
blocker*
TARGET 20 mmHg systolicor>10 mmHg diastolic above target
-
8/3/2019 Treatment En 2011 Final
51/83
V. Treatment Algorithm for Isolated SystolicHypertension without Other Compelling Indications
INITIAL TREATMENT AND MONOTHERAPY
Thiazide
diuretic
Long-acting
DHPCCB
Lifestyle modification
therapy
ARB
TARGET
-
8/3/2019 Treatment En 2011 Final
52/83
V. Add-on therapy for Isolated SystolicHypertension without Other Compelling Indications
CONSIDER
Nonadherence Secondary HTN Interfering drugs or
lifestyle White coat effect
If blood pressure is still not controlled, or there are adverse
effects, other classes of antihypertensive drugs may be
combined (such as ACE inhibitors, alpha adrenergic
blockers, centrally acting agents, or nondihydropyridine
calcium channel blocker).
If partial response to monotherapy
Long-acting
DHPCCB
Triple therapy
Thiazide
diureticARB
Dual combinationCombine first line agents
-
8/3/2019 Treatment En 2011 Final
53/83
V. Summary: Treatment of Isolated SystolicHypertension without Other Compelling Indications
CONSIDER
Nonadherence
Secondary HTN Interfering drugs or
lifestyle White coat effect
Thiazidediuretic
Long-actingDHPCCB
Dual therapy
Triple therapy
Lifestyle modification
therapy
ARB
TARGET
-
8/3/2019 Treatment En 2011 Final
54/83
Choice of Pharmacological Treatmentfor Hypertension
Individualized treatment
Compelling indications: Ischemic Heart Disease
Recent ST Segment Elevation-MI or non-ST Segment Elevation-MI
Left Ventricular Systolic Dysfunction
Cerebrovascular Disease
Left Ventricular Hypertrophy Non Diabetic Chronic Kidney Disease
Renovascular Disease
Smoking
Diabetes Mellitus With Nephropathy
Without Nephropathy
Global Vascular Protection for Hypertensive Patients Statins if 3 or more additional cardiovascular risks
Aspirin once blood pressure is controlled
-
8/3/2019 Treatment En 2011 Final
55/83
VI. Treatment of Hypertension in Patients withIschemic Heart Disease
Caution should be exercised when combining a non DHP-CCB and a beta-blocker If abnormal systolic left ventricular function: avoid non DHP-CCB (Verapamil or
Diltiazem) Dual therapy with an ACEI and an ARB are not recommended in the absence of
refractory heart failure The combination of an ACEi and CCB is preferred
1. Beta-blocker2. Long-acting CCB
Stable angina
ACEI are recommended for most
patients with establishedC
AD*ARBs are not inferior to ACEI in IHD
Short-actingnifedipine
*Those at low risk with well controlled risk factors may not benefit from ACEI therapy
-
8/3/2019 Treatment En 2011 Final
56/83
VI. Treatment of Hypertension in Patients with Recent STSegment Elevation-MI or non-ST Segment Elevation-MI
Long-acting
DihydropyridineCCB*
Beta-blocker
and ACEI or
ARB
Recent
myocardialinfarction
HeartFailure
?
NO
YES
Long-acting CCB
If beta-blockercontraindicated
or not effective
*Avoid non dihydropyridine CCBs (diltiazem, verapamil)
-
8/3/2019 Treatment En 2011 Final
57/83
VII. Treatment of Hypertension with LeftVentricular Systolic Dysfunction
Beta-blockers used in clinical trials were bisoprolol, carvedilol and metoprolol.
If additional therapy is needed: Diuretic (Thiazide for hypertension; Loop for volume control) for CHF class III-IV or post MI: Aldosterone Antagonist
Systoliccardiac
dysfunction
ACEI and Beta blocker if ACEI intolerant: ARBTitrate doses of ACEI or ARB to those used in clinical trials
If ACEI and ARB are contraindicated: Hydralazine and Isosorbidedinitrate in combination
If additional antihypertensive therapy is needed:
ACEI / ARB Combination Long-acting DHP-CCB (Amlodipine)
NondihydropyridineCCB
-
8/3/2019 Treatment En 2011 Final
58/83
Viii. Treatment of Hypertension in Association With StrokeAcute Stroke: Onset to 72 Hours
Treat extreme BP elevation (systolic
> 220 mmHg, diastolic > 120 mmHg)
by 15-25% over the first 24 hour
with gradual reduction after.
If eligible for thrombolytic therapytreat very high BP (>185/110 mmHg)
Acute
ischemic
Stroke
Avoid excessive lowering of BP which can exacerbate ischemia
-
8/3/2019 Treatment En 2011 Final
59/83
VIII. Treatment of Hypertension in Association With StrokeAfter the acute Phase of Stroke or TIA
Strongly consider blood pressure reduction in all patients
after the acute phase of stroke or TIA .
Target BP < 140/90 mmHg
An ACEI / diuretic
combination is preferred
StrokeTIA
Combinations of an ACEI with an ARB are not recommended
-
8/3/2019 Treatment En 2011 Final
60/83
IX. Treatment of Hypertension in Patients withLeft Ventricular Hypertrophy
Hypertensive patients with left ventricular hypertrophy should
be treated with antihypertensive therapy to lower the rate of
subsequent cardiovascular events
Vasodilators:
Hydralazine, Minoxidil can increase LVH
Left ventricular
hypertrophy
- ACEI
- ARB,- CCB- Thiazide Diuretic- BB (if age below 60)*
X T f H i i P i i h
-
8/3/2019 Treatment En 2011 Final
61/83
X. Treatment of Hypertension in Patients withNon Diabetic Chronic Kidney Disease
Chronic kidney
disease and
proteinuria *
ACEI/ARB:Bilateral renalartery stenosis
ACEI or ARB (if ACEI tolerated)
Combination with other agents
Additive therapy: Thiazide diuretic.
Alternate: If volume overload: loop diuretic
Target BP: < 130/80 mmHg
* albumin:creatinine ratio [ACR] > 30 mg/mmol
orurinary protein > 500 mg/24hr
Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB
Combinations of a ACEI and a ARB are specifically not recommended in the absence of proteinuria
XI T t t f H t i i P ti t ith
-
8/3/2019 Treatment En 2011 Final
62/83
XI. Treatment of Hypertension in Patients withRenovascular Disease
Close follow-up and intervention (angioplasty and stenting or surgery) should
be considered for patients with: uncontrolled hypertension despite therapywith three or more drugs, or deteriorating renal function, or bilateral
atherosclerotic renal artery lesions (or tight atherosclerotic stenosis in asingle kidney), or recurrent episodes of flash pulmonary edema.
Does not imply specific
treatment choice
Renovascular
disease
Caution in the use of ACEI or ARB inbilateral renal artery stenosis orunilateral disease with solitary kidney
-
8/3/2019 Treatment En 2011 Final
63/83
XII. Treatment ofHypertension in association
with Diabetes Mellitus2011 Canadian Hypertension
Education ProgramRecommendations
XII T t t f H t i i i ti
-
8/3/2019 Treatment En 2011 Final
64/83
XII. Treatment of Hypertension in associationwith Diabetes Mellitus
Threshold equal or over 130/80 mmHg and Target below 130/80 mmHg
with
Nephropathy*
*Urinary albumin to creatinine
ratio > 2.0 mg/mmol in men or
> 2.8mg/mmol in women*
Diabetes
without
Nephropathy**
Isolated
Systolic
Hypertension
Systolic-
diastolic
Hypertension
* based on at least 2 of 3 measurements
A combination of 2 first line drugs maybe considered as initial therapy if theblood pressure is >20 mmHg systolicor>10 mmHg diastolic above target
Combinations of an ACEI with an ARB are specifically
not recommended in the absence of proteinuria
XII T t t f H t i i i ti
-
8/3/2019 Treatment En 2011 Final
65/83
XII. Treatment of Hypertension in associationwith Diabetic Nephropathy
IfCreatinine over 150 mol/L or creatinine clearance below 30 ml/min ( 0.5
ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control
of volume is desired
THRESHOLD equal or over 130/80 mmHg and TARGET below 130/80 mmHg
DIABETES
with
Nephropathy
ACE Inhibitor
or ARB
IF ACEI and ARB arecontraindicated or not
tolerated,SUBSTITUTE
Long-acting CCB or
Thiazide diuretic
Addition of one or more ofLong-acting CCB or Thiazidediuretic
3 - 4 drugs combination maybe needed
Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB
2011 C di H t i Ed ti
-
8/3/2019 Treatment En 2011 Final
66/83
2011 Canadian Hypertension EducationProgram (CHEP)
Important messages from past recommendations
Patients with diabetes are at high cardiovascular risk
Most patients with diabetes have hypertension
Treatment of hypertension in patients with diabetes reduces
total mortality, myocardial infarction, stroke, retinopathy andprogressive renal failure rates.
Treating hypertension in patients with diabetes reduces deathand disability and reduces health care system costs
In diabetes, TARGET
-
8/3/2019 Treatment En 2011 Final
67/83
XII. Treatment of Systolic-DiastolicHypertension without Diabetic Nephropathy
1. ACE Inhibitor or ARB or
2. Dihydropyridine CCB or
Thiazide diuretic
IF ACE Inhibitor and ARB andDHP-CCB and Thiazide arecontraindicated or nottolerated,
SUBSTITUTE
Cardioselective BB* or
Long-acting NON DHP-CCB
More than 3 drugs may be needed to reach target values for diabetic patients
* Cardioselective BB: Acebutolol, Atenolol, Bisoprolol , Metoprolol
Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg
Combination of first line
agents
Addition of one or more of:Cardioselective BB orLong-acting CCB
Diabetes
without
Nephropathy
DHP: dihydropyridine
Combinations of an ACE Inhibitor with an ARB are specifically not recommended in theabsence of proteinuria
ACCORD St d R lt d ti l f l k f
-
8/3/2019 Treatment En 2011 Final
68/83
ACCORD Study: Results and rational for lack ofimpact on BP recommendations
Overall BP study was neutral with no benefit of systolic target< 120 mmHg vs < 140 mmHg for primary outcome, yet:
Power issue: Annual rate of primary outcome 1.87% in theintensive arm versus 2.09% in the standard arm vs 4%/yearevent rate projected during sample size calculations
Significant interaction between BP and glycaemia controlstudies such that those in usual care glycaemia group (A1c7%+) had a significant improvement in primary outcome withlower BP target
Secondary outcome for stroke reduction showed a benefit forlower BP target
Therefore no clear evidence supporting a change in BP targetsfor people with diabetes at this point
ACCORD study NEJM 2010
XII Treatment of Hypertension in association
-
8/3/2019 Treatment En 2011 Final
69/83
XII. Treatment of Hypertension in associationwith Diabetes Mellitus: Summary
More than 3 drugs may be needed to reach target values for diabetic patients
If Creatinine over 150 mol/L or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for athiazide diuretic if control of volume is desired
Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg
Diabetes
with
Nephropathy
> 2-drugcombinations
ACE Inhibitor
or ARB
without
Nephropathy
1. ACE Inhibitoror ARB
or
2. DHP-CCB orThiazidediuretic
Monitor serum potassium and creatinine carefully in patients withCKD prescribed an ACEI or ARB
Combinations of an ACEI with an ARB are specifically not recommended in the absence of proteinuria
A combination of 2 first linedrugs may be considered asinitial therapy if the bloodpressure is >20 mmHg systolicor >10 mmHg diastolic abovetarget. Combining an ACEi and
a DHP-CCB is recommended.
XIII Treatment of Hypertension for Patients
-
8/3/2019 Treatment En 2011 Final
70/83
The benefits of treating smokers with beta-
blockers remain uncertain in the absence of a
specific indication like angina or post-MI
Smoking Beta-blocker
XIII. Treatment of Hypertension for PatientsWho Use Tobacco
MRCWorking Party. MRC trial of treatment of mild hypertension: 1985 Jul 13;291(6488):97-104.
-
8/3/2019 Treatment En 2011 Final
71/83
XIV. Overall VascularProtection for Patients with
Hypertension2011 Canadian Hypertension
Education ProgramRecommendations
Most hypertensive Canadians have other
-
8/3/2019 Treatment En 2011 Final
72/83
Most hypertensive Canadians have othercardiovascular risks
Assess and manage hypertensive patients forsmoking, dyslipidemia and dysglycemia (impairedfasting glucose or diabetes) abdominal obesity,unhealthy eating and physical inactivity.
Discuss global risk using analogies that describecomparative risk such as Cardiovascular Age,Vascular Age or Heart Age to inform patients oftheir risk status and to improve the effectiveness of
risk factor modification.
XIV Vascular Protection for Hypertensive
-
8/3/2019 Treatment En 2011 Final
73/83
XIV. Vascular Protection for HypertensivePatients: Statins
In addition to currentCanadian recommendations on management
of dyslipidemia, statins are recommended in high-risk
hypertensive patients with established atherosclerotic disease
or with at least 3 of the following criteria:
Male
Age 55 or older
Smoking
Total-C/HDL-C ratio of 6mmol/L or higher
Family History of PrematureCV disease
LVH
ECG abnormalities
Microalbuminuria or Proteinuria
ASCOT-LLA Lancet 2003;361:1149-58
XIV Vascular Protection for Hypertensive
-
8/3/2019 Treatment En 2011 Final
74/83
XIV. Vascular Protection for HypertensivePatients: ASA
Consider low dose ASA
Caution should be exercised if BP is not controlled.
New Patient Resources For
-
8/3/2019 Treatment En 2011 Final
75/83
New Patient Resources ForHypertension On Line
www.hypertension.ca/tools - Download current resources for theprevention and control of hypertension
www.htnupdate.ca -To keep up to date with the latest evidence andresources
www.myBPsite.ca - Have your patients sign up to access the latest
hypertension resources www.lowersodium.ca - Tools and resources for healthcareprofessionals to use in educating other healthcare professionals, thepublic or patients about the risks of high dietary sodium in Canada.
www.sodium101.ca -To access a simple to use demonstration of foodsodium content for your patients
www.heartandstroke.ca/BP -To monitor home blood pressure andencourage self management of lifestyle
http://www.hypertension.qc.ca/ - Socit Qubcoise dhypertensionartrielle
-
8/3/2019 Treatment En 2011 Final
76/83
Public translation of CHEP recommendations
Hypertension recommendations for the public
Translated into 4 Indo-Asian languages (2007)
Based on CHEP guidelines (annually updated)
Download at www.hypertension.ca
-
8/3/2019 Treatment En 2011 Final
77/83
Sodium Slide Kit
Tool used to educate the public and patients ondietary sodium.
Annually updated.
Download at www.hypertension.ca
-
8/3/2019 Treatment En 2011 Final
78/83
Brief Hypertension Action Tool
Can by used by a healthcare provider to better inform and engage a
hypertensive patient to ultimately become more active in their
care.
Involves 3 Action Tools:
Action Tool # 1 Explains High BP
Action Tool # 2 Self-management of
lifestyle
Action Tool # 3 Proper home measurement& information about medication
Download at www.hypertension.ca
Measuring Blood Pressure the Right Way
-
8/3/2019 Treatment En 2011 Final
79/83
Measuring Blood Pressure the Right Way Poster
Posters (24 by 36)can be ordered fromour website.
Brief highlights:1. Preparing to taking your
blood pressure
2. Using endorsed BPdevices.
Download at www.hypertension.ca
-
8/3/2019 Treatment En 2011 Final
80/83
Summary I
Regarding the treatment of hypertension, therecommendations endorse:
Know the current blood pressure of all your patients
Most Canadians will develop hypertension during their lives.
Routine assessment of blood pressure is required for earlydetection and risk management
Encourage the use of approved devices and propertechnique to measure blood pressure at home.
Most can assess blood pressure at home. Home measurement
can confirm a diagnosis of hypertension, improve adherence totherapy and control rates and detect patients with white coat ormasked hypertension.
-
8/3/2019 Treatment En 2011 Final
81/83
Summary II
Regarding the treatment of hypertension, therecommendations endorse:
Assess and manage CV risk in hypertensives
high dietary sodium intake, smoking, dyslipidemia,dysglycemia, abdominal obesity, unhealthy eating, and physical
inactivity.
LIFESTYLEMODIFICATION
Sustained lifestyle modification is the cornerstone for theprevention and control of hypertension and the management ofcardiovascular disease. Encourage patients to reduce theirsodium intake according to Health Canadas recommendations.
-
8/3/2019 Treatment En 2011 Final
82/83
Summary III
Regarding the treatment of hypertension, therecommendations endorse:
TREATING TO TARGET BP Treat blood pressure to less than
-
8/3/2019 Treatment En 2011 Final
83/83
For your patients ask themto sign up atwww.myBPsite.ca for freeaccess to the latestinformation & resources on
high blood pressure
For health care professionals sign up atwww.htnupdate.ca forautomatic updates and oncurrent hypertension
educational resources